HeartSciences Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $10.9M
- Price
- $2.80
- % Change (Daily % change from the live per-ticker quote feed.)
- +11.55%
- Volume
- 198.8K
About
HeartSciences Inc. is a medical technology company dedicated to augmenting the clinical utility of electrocardiograms (ECGs) by integrating artificial intelligence (AI). The firm develops AI-enhanced ECG (AI-ECG) solutions, including an algorithm specifically designed to detect impaired cardiac relaxation or other forms of cardiac dysfunction, whether caused by heart disease or the natural aging process. Among its offerings is the MyoVista wavECG device, a 12-lead resting ECG that provides comprehensive diagnostic information concerning cardiac function alongside conventional ECG data in a single examination. Furthermore, the company offers MyoVista Insights, a cloud-based platform capable of hosting its AI-ECG algorithms across various ECG hardware systems. Established in 2007, HeartSciences Inc. operates from its headquarters in Southlake, Texas. The company was formerly named Heart Test Laboratories, Inc. until its rebranding to HeartSciences Inc. in October 2024.
Quick stats
Shares outstanding3.9M
Computed float2.8M
Float / shares71.0%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001468492
Websitehttps://heartsciences.com
AI Summary
AI-generated1/19
standardbullishoperations update
Fortitude Provides Second Quarter 2026 Financial and Operating Highlights
Fortitude, HeartSciences' pending merger partner, reported Q2 revenue of $20.9 million and Adjusted EBITDA of $8.5 million, mining 33,646 ZEC with a 4.0 GSol/s hash rate.
To support the transaction expected to close in H2 2026, Fortitude invested $1 million in HeartSciences, purchasing 411,522 shares at a VWAP of $2.43—a 22% premium to the prior close.
Following the subscription, Fortitude owns approximately 9.4% of HeartSciences, solidifying its commitment to the business combination.